{"id":"W2032804887","doi":"10.1038/eye.2012.174","title":"Pilot study to evaLuate the role of high-dose rAnibizumab 2.0 mg in the management of neovascular age-related macular degeneration in patients with perSistent/recurrenT macular fluid <30 days following treatment with intravitreal anti-VEGF therapy (the LAST Study)","year":2012,"lang":"en","type":"article","venue":"Eye","topic":"Retinal Diseases and Treatments","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":false,"ca_institutions":"Columbia College","funders":"","keywords":"Ranibizumab; Medicine; Macular degeneration; Ophthalmology; Visual acuity; Pro re nata; Choroidal neovascularization; Randomized controlled trial; Bevacizumab; Prospective cohort study; Regimen; Ophthalmic pathology; Neuro-ophthalmology; Surgery; Glaucoma; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002169116,0.001255087,0.002458614,0.0003355359,0.0004999288,0.0007678699,0.001033048,0.001254345,0.002910689],"category_scores_gemma":[0.001446773,0.0005500905,0.001854065,0.0003252032,0.001016236,0.001002406,0.0005098738,0.002241716,0.0007591007],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007695445,"about_ca_system_score_gemma":0.001510739,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001996344,"about_ca_topic_score_gemma":0.002775179,"domain_scores_codex":[0.9992982,0.0003448178,0.000047569,0.0001051872,0.00005666462,0.0001475154],"domain_scores_gemma":[0.9984766,0.0003324942,0.000245658,0.0001585619,0.00009787599,0.0006888225],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8493507,0.09178766,0.008294322,0.0002349874,0.0009702871,0.0004757455,0.0001820765,0.0005881972,0.02572851,0.000105271,0.0009331956,0.02134909],"study_design_scores_gemma":[0.2562278,0.7217082,0.01886115,0.00001092282,0.000487558,0.0001715006,0.00004723319,0.0003978031,0.001396836,0.00004994751,0.0006179452,0.00002320282],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9969464,0.0005050998,0.0002580403,0.0001854864,0.00008871278,0.0009753237,0.0003618803,0.00003880178,0.0006403898],"genre_scores_gemma":[0.9946554,0.0003507493,0.001350343,0.0004386486,0.0003436596,0.001322847,0.0007406347,0.00001176079,0.0007860619],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002910689,"threshold_uncertainty_score":0.01147151,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0156184576577394,"score_gpt":0.2665659549063277,"score_spread":0.2509474972485883,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}